



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2025-26/42
September 24, 2025

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Sub: Presentation to Shareholders

**Ref: Regulation 30 of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015**

Please find attached herewith presentation made to the shareholders of the Company at the 40th Annual General Meeting held today i.e. **September 24, 2025** for your records.

Kindly take the same on record.

Thanking you,

Yours faithfully,
FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M.No.: F12932



Aarti Drugs Ltd.

Aarti Drugs Limited

**Annual General Meeting
September 24, 2025**

FY 2024-25

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Aarti Drugs Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.


This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

Company & Business Overview



Journey



Leadership in API Manufacturing

Over a decade, API manufacturing has transitioned towards highly regulated, specialized business

1	Largest producer of Nimesulide in the world
2	Largest producer of Ketoconazole in the world
3	Largest producer of Metronidazole Benzoate in the world
4	Largest producer of Tinidazole in the world
5	Largest producer in Fluoroquinolones group in the world
6	One of the leading producers of Metformin in the world
7	Largest producer of Metronidazole in India

14

Manufacturing Facilities

5,088

MT/Monthly Capacity

80+

Finished Products

50+

API Molecules

~2,067

Employees

~35%

Export Revenue


1,26,642

Sq.m. Plant Area

100+

Presence across countries

Manufacturing Footprint



Maps not to scale . All data , information , and maps are provided " as is " without warranty or any representation of accuracy

Presence Across APIs, Formulation, Specialty Chemicals, Intermediates Segments




Active Pharmaceuticals Ingredients (API)

- ✓ Leading API producer with 50+ molecules across therapeutic categories including antibiotics, antiprotozoals, anti-inflammatories, anti-diabetics, anti-fungals and cardioprotectant
- ✓ Global Leader:
 - Largest manufacturer of 5 molecules globally
 - Among the top producers of 2 additional molecules worldwide
- ✓ API Infrastructure:
 - 9 manufacturing units contributing ~80% of total revenues
 - Installed capacity: 45,511 MTPA



Formulations

- ✓ Diversified into formulations in 2014 via wholly owned subsidiary.
- ✓ Flexible manufacturing model: In-house + outsourced production backed by strong R&D
- ✓ UKMHRA / PICS approved
- ✓ WHO-GMP approved plant in Baddi, Himachal Pradesh
- ✓ Oncology formulation is USFDA approved
- ✓ Installed capacity:
 - 3 billion tablets
 - 300 million capsules



Specialty Chemicals, Intermediates & Others

- ✓ Backward integrated to supply intermediates for antibiotics, antifungals, anti-inflammatories, and cardiovascular APIs.
- ✓ Manufacturer of specialty chemicals in Benzene and Chloro-sulphonic chemistries
- ✓ Installed capacity: 13,742 MTPA

Diversified Geographic Presence

North America

8%
FY24

11%
FY25

Latin America

10%
FY24

14%
FY25

Africa

11%
FY24

11%
FY25

Europe

14%
FY24

12%
FY25


Asia

57%
FY24

52%
FY25



Market Segmentation



Presence in 100+ Countries across 6 Continents ensures diversification and risk minimization

Maps not to scale . All data , information , and maps are provided " as is " without warranty or any representation of accuracy

Strong R&D thrust on continuous innovation

R&D Center at Tarapur

- Supports manufacturing facilities at Tarapur and Sarigam on API process development
- Pilot plant used for kilo scale manufacturing
- Recognized by Department of Science and Industrial Research (DSIR) Government of India
- Frequent visits of Experts and Professors from ICT and Council of Scientific and Industrial Research (CSIR) for guidance for product development

R&D Center at Turbhe

- Supports development of complex generics for in-house formulation business
- Developing complex oral solids for Regulated as well as Emerging markets

- ✓ Well supported by in-house project management team to ensure timely implementation of new products on commercial scale
- ✓ Developed 30+ APIs (new and existing) in last 5 years
- ✓ Developing new age Formulation products for Europe, USA, Australia, Brazil, Canada & Chile for Day 1 launches
- ✓ Plans to expand R&D capabilities to develop complex Semi solids (creams & ointments) as well as Oral liquids
- ✓ Majority of products developed with integrated API provides an end-to-end control

2

Doctorates

79

Master Graduated (M.Sc.)

6

Technicians

Rs. 46 Crores

R&D Spends (FY25)

50

Graduates (B.Sc.) & Engineers

Capex of Rs. 600 crores nearly complete; Boosting capacity, margins

Anti-diabetics

- ✓ With a manufacturing capacity exceeding 1,450 TPM, ADL is one of the leading Metformin manufacturers in the world.
- ✓ Aiming for higher utilization. In future planning for additional 350 TPM of brownfield expansion
- ✓ The launch of Gliptins will further enhance and solidify the position of this category
- ✓ The greenfield project at Sayakha, Gujarat, dedicated to backward integration of anti-diabetic products along with few more intermediates, has commenced trial production which is expected to stabilize soon. This is anticipated to contribute meaningfully to the Company's profitability over a long period of time

Antiprotozoals

- ✓ Enhancing the position in the Indian market through a brownfield expansion focussed on selected products, which will increase production capacity by approximately 40%
- ✓ Secured approval to market the products in China, expanding market reach into new territories
- ✓ By pursuing incremental expansions and improving downstream products within the antiprotozoals segment, the Company is poised to accelerate our growth trajectory

Formulations

- ✓ Commenced commercial operations in Latin America and a few African markets along with undertaking new registrations in export markets and government tenders
- ✓ Formulation Oncology Investments Plant is USFDA approved
- ✓ Currently, pursuing expansion into new geographies, alongside toll manufacturing of formulations
- ✓ Filed ~330 registrations across 16 geographies and established a foreign subsidiary to seize emerging opportunities

Anti-inflammatory

- ✓ Targeting highly regulated markets, undertaken the construction of a multi-purpose facility to better serve our customers.
- ✓ The brownfield expansion of existing facilities is underway for few therapeutic drugs, further driving growth in this segment.
- ✓ The enhanced capacity is expected to yield revenues of ~Rs. 35-50 Crores annually based on product selection.

Operational Scale-up at Tarapur Greenfield Project

- ✓ The Salicylic Acid plant at Tarapur has commenced operations and is gradually scaling up production and is targeting a cumulative capacity of ~1,600 tonnes per month by the end of 2025-26.
- ✓ This is expected to contribute meaningfully to long-term profitability

Brownfield / Greenfield Capacity Expansion

Backward Integration

De-bottlenecking

Asset Turn - 2.5x

Revenue:

Rs. 1,200 crores

+

Captive consumption:

Rs. 300 crores

Revenue Growth

Higher Margins

Higher RoCE



Environment

- Zero Liquid Discharge (ZLD)



- Carbon Footprint Reduction



- Eco-friendly Packaging



- Efficient Utilities & Green Technologies



Social

- Healthcare Initiatives



- Woman Empowerment



- Fair Trade Practices



- Gender Diversity



Governance

- Stakeholder Responsibility



- Risk Management Governance



- Adherence to Regulatory Compliance



- Board Composition and Governance





Corporate Social Responsibility

Donation of Ambulance & Garbage Van, Supply of medicines, Repair & Re-painting at Zilla Parishad School, Distribution of School uniforms & notebooks



Tree Plantation Programs

लोकमत

आरती ड्रग्स उद्योग समूह करणार ३,५०० झाडांची लागवड

तारापूर एमआयडीसीत कचराडेपोच्या जागी साकारतेय नंदनवन!

लोकमत न्यूज नेटवर्क
बोईसर : तारापूर एमआयडीसीतील भोक्ता प्रमाणन निकषांनी असलेल्या शिवाजीनगरचे रहिवासी औद्योगिक क्षेत्रातील टी डीएमपीएल प्रॉपर्टी वाहतूक असणाऱ्या रस्त्यावर धरातील कचरा टाकतात. यामुळे या जागेला कचरा डेपोचे स्वरूप आले. पण स्थानिक नागरिकांनी कचरा डेपो केलेल्या जागेवर तारापूर येथील आरती ड्रग्स उद्योग समूहाने नंदनवन फुलवण्याचा निर्धार केला आहे.

इथल्या कचरा टाकल्या जाणाऱ्या त्या जागेवर शिवाजी बाबायाम्बरीही फॅक्ट्री (मिथायली जेनरेशन) या पद्धतीने भोक्ता प्रमाणात पुढे लागवड करून नंदनवन साकारणार असल्याने आताच्या रुग्णीयुक्त जागेत भरिघवत तारापूर एमआयडीसीत असलेल्या रस्त्यावर कचरा टाकला जातो तिथे नंदनवन फुलवण्याचा निर्धार आरती ड्रग्स उद्योग समूहाने केला आहे. शनिवारी मान्यवरांच्या उपस्थितीत वृक्षारोपण करून त्याचे उद्घाटन करण्यात आले.

विशेषण आहेत. आरती ड्रग्स उद्योग समूहाच्याकडील उभापरण्यात येणाऱ्या मिथायली बाबायाम्बरीही फॅक्ट्रीच्या जागेवर शनिवारी वृक्षारोपण करून उद्घाटन करण्यात आले.

सरपंच विदुला पट्टीन, माजी सरपंच संजय पाटील व गिरीश राऊत, महासुप्रदुषण नियंत्रण मंडळाच्या तारापूर शाखाचे उपाध्यक्ष अधिकारी प्रशांत गायकवाड, क्षेत्र अधिकारी आचिकारी नीलेश पाटील, संजय पाटील, सालवड ग्रामपंचायतीच्या सदस्या सुवर्णा पाटील, प्रतीक्षा मोरे, सुचिता पाटील, पाली उपसरपंच अर्पित मोरे व कविता राऊत, माजी सदस्य...

सालवड ग्रामपंचायतीचे मिळाले सहकार्य
लेकटो टन कचरा उचलून ती जागा सालवड ग्रामपंचायतीच्या सहकार्याने स्वच्छ करून तेथे आरती ड्रग्सच्या सोपरावर फडालून ६५०० रुबेअर फुड जागेवर कुपण करून सुमारे २०० प्रकारची विविध जातीची ३५०० झाडे लागली जाणार आहेत.






Water Conservation

We funded the project implemented by Naam Foundation for removal of silt from the water distribution channels of the Paithan right and left canals in Beed, Parbhani and Nanded district of Maharashtra. The water to these canals is sourced from Jayakwadi Dam at Paithan.

Nearly 1,83,000 hectares of agricultural land is irrigated by Paithan Dam

Benefitting around 2,00,000 farmers

Impact of Project

- Continuous water supply will be ensured for all beneficiary farmers from 18 villages located along the canal.
- It will help increase underground water level.

Field Impact

- Water Availability: The positive effects show that water has reached the tail villages for the first time.
- Crop Yields: There will be potential increases in crop yields due to enhanced water management.
- Collaboration: Strengthened collaboration and communication between villages are enabling smoother and more efficient canal water distribution.



Tree Plantation

Miyawaki forests are multi-layered forests built with native plants, with the potential to turn into a full-fledged dense forest in a span of 3-5 years. This is a very effective and quick technique for urban reforestation.

We are currently transforming a garbage dumping area near Karajgam Talav in Tarapur, Maharashtra, into a Miyawaki forest through extensive tree planting efforts. We have also undertaken tree plantation drives at multiple locations near our factories in Tarapur and Sarigam.

3,000+
Total Trees Planted




Business & Financial Highlights



FY25 Results Highlights


Total Revenue

(Rs. Crs.)




EBITDA & EBITDA Margin

(Rs. Crs.)




PAT & PAT Margin

(Rs. Crs.)




FY25 Segmental Break-up

FY 24




FY 25



Q1 FY26 Results Highlights


Total Revenue

(Rs. Crs.)




EBITDA & EBITDA Margin

(Rs. Crs.)




PAT & PAT Margin


(Rs. Crs.)



Segmental Revenue



Therapeutic-wise Revenue* (Within API Segment)



Note: EBITDA includes other income & excludes exceptional items
* As of Q1 FY26, Therapeutic revenue Includes sale to Pinnacle Life Science


Historical Financial Performance



Historical Consolidated Performance


Total Revenue

(in Rs. Crore)




EBITDA & EBITDA Margin

(in Rs. Crore)




PAT & PAT Margin

(in Rs. Crore)




Earnings Per Share

(in Rs.)




Net Worth


(in Rs. Crore)




Leverage (X)



RoCE (%)



RoE (%)



Note: EBITDA includes other income & excludes exceptional items

Distribution Policy

Considering various financial parameters, the Company may elect to distribute

~15% to 30%

of Consolidated Net Profits



Distributed ~Rs. 69.48 Crore as Dividend over last 7 years



Distributed ~ Rs. 229.15 crore through buyback of shares over last 7 years



Distributed ~ Rs. 278 crore in form of dividend & buyback of shares over last 7 years



Aarti Drugs Ltd.

Thank You

Company: Aarti Drugs Limited

CIN: L37060MH1984PLC055433



Aarti Drugs Ltd.

Mr. Rushikesh Deole

investorrelations@aartidrugs.com / +91 22 24048199

www.aartidrugs.co.in

Investor Relations: Strategic Growth Advisors (SGA)

CIN: U74140MH2010PTC204285

SGA Strategic Growth Advisors

Mr. Deven Dhruva

deven.dhruva@sgapl.net

Tel: +91 98333 73300